Results 101 to 110 of about 5,534,789 (298)
Adverse Outcome Pathway (AOP) is a useful tool to glean mode of action (MOE) of a chemical. However, in order to use it for the purpose of risk assessment, an AOP needs to be quantified using in vitro or in vivo data.
Shigeaki Ito+8 more
doaj +1 more source
A RE-ASSESSMENT OF THE GASTRIC LESION IN PERNICIOUS ANAEMIA [PDF]
Hugo Magnus
openalex +1 more source
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen+13 more
wiley +1 more source
Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha+6 more
wiley +1 more source
Pure All-trans Vitamin A Acetate and the Assessment of Vitamin A Potency by Spectrophotometry [PDF]
J. Boldingh+9 more
openalex +1 more source
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini+11 more
wiley +1 more source
Assessment of the level of nutrition. Urinary excretion of aneurin at varying levels of intake [PDF]
Y. L. Wang, John Yudkin
openalex +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi+6 more
wiley +1 more source